top of page
Browse by category
Search
Ascletis completes enrolment in US study for once-monthly subcutaneous depot treatment GLP-1R agonist ASC30 for obesity
Ascletis Pharma has completed enrolment in the US Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity. All 65 participants are obese or overweight with at least one weight-related comorbidity. The Phase IIa study of ASC30 once-monthly SQ depot treatment formulation is a 12-week, randomised, double-blind, placebo-controlled and multi-centre study co
First participants dosed in Ascletis’ 13-week Phase IIa study of oral GLP-1r agonist ASC30
The first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in Ascletis Pharma’s US...
Positive results for Ascletis’ oral GLP-1ra ASC30
Ascletis Pharma has announced positive topline results from its US single ascending dose (SAD) study of ASC30 oral tablet in patients...
Browse by tag
bottom of page